Chantelle Bozynski

Dr. Chantelle Bozynski

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2016 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
JCJames L. Cook
James L. Cook
JSJames P. Stannard
James P. Stannard
ASAaron M. Stoker
Aaron M. Stoker
CBChantelle Bozynski
Chantelle Bozynski
KKKeiichi Kuroki
Keiichi Kuroki
FPFerris M. Pfeiffer
Ferris M. Pfeiffer
Background: Osteochondral allograft (OCA) transplantation provides a biological treatment option for functional restoration of large articular cartilage defects in multiple joints. While successful outcomes after OCA transplantation have been linked to viable donor chondrocytes, the importance of donor cell viability has not been comprehensively validated. Purpose: To use a canine model to determine the importance of donor chondrocyte viability at the time of implantation with respect to functional success of femoral condylar OCAs based on radiographic, gross, cell viability, histologic, biochemical, and biomechanical outcome measures. Study Design: Controlled laboratory study. Methods: After approval was obtained from the institutional animal care and use committee, adult female dogs (N = 16) were implanted with 8-mm cylindrical OCAs from male dogs in the lateral and medial femoral condyles of 1 knee. OCAs were preserved for 28 or 60 days after procurement, and chondrocyte viability was quantified before implantation. Two different storage media, temperatures, and time points were used to obtain a spectrum of percentage chondrocyte viability at the time of implantation. A successful outcome was defined as an OCA that was associated with graft integration, maintenance of hyaline cartilage, lack of associated cartilage disorder, and lack of fibrillation, fissuring, or fibrous tissue infiltration of the allograft based on subjective radiographic, gross, and histologic assessments at 6 months after implantation. Results: Chondrocyte viability ranged from 23% to 99% at the time of implantation. All successful grafts had >70% chondrocyte viability at the time of implantation, and no graft with chondrocyte viability <70% was associated with a successful outcome. Live-dead stained sections and histologic findings with respect to cell morphological features suggested that successful grafts were consistently composed of viable chondrocytes in lacunae, while grafts that were not successful were composed of nonviable chondrocytes with infiltration of fibroblasts from the surrounding recipient tissues. In situ polymerase chain reaction (fluorescence in situ hybridization [FISH]) assays were performed in an attempt to distinguish donor (male) cells from recipient (female) cells. Unfortunately, this technique was exceptionally difficult to perform on intact articular cartilage sections, and consistent, repeatable data could not be obtained from this testing. However, the data did support histologic and live-dead data, which strongly suggested that successful grafts retained viable donor (male) chondrocytes and unsuccessful grafts degraded and were replaced by fibrous tissue populated with recipient (female) fibroblasts. Conclusion: Viable chondrocytes in OCAs at the time of transplantation are primarily responsible for maintenance of donor articular cartilage health in the long term. Clinical Relevance: Optimizing chondrocyte viability in all aspects of OCA transplantation—including procurement, processing, storage, transportation, and surgical implantation—needs to be a primary focus for OCA clinical use.

17 July 2014 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
PDF file
JCJames L. Cook
James L. Cook
ASAaron M. Stoker
Aaron M. Stoker
JSJames P. Stannard
James P. Stannard
KKKeiichi Kuroki
Keiichi Kuroki
CCCristi R. Cook
Cristi R. Cook
CHClark T. Hung
Clark T. Hung
Osteochondral allografting is an option for successful treatment of large articular cartilage defects. Use of osteochondral allografting is limited by graft availability, often because of loss of chondrocyte viability during storage.

22 September 2017 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
ASAaron M. Stoker
Aaron M. Stoker
JSJames P. Stannard
James P. Stannard
KKKeiichi Kuroki
Keiichi Kuroki
CBChantelle Bozynski
Chantelle Bozynski
FPFerris M. Pfeiffer
Ferris M. Pfeiffer
JCJames L. Cook
James L. Cook
Background: Fresh osteochondral allografts (OCAs) are limited in availability. The Missouri Osteochondral Allograft Preservation System (MOPS) has been reported to effectively preserve OCAs twice as long as current tissue bank protocols in preclinical studies. Hypothesis: The viable chondrocyte density (VCD) in OCAs preserved for up to 70 days using the MOPS will not be significantly different from day 0, and the VCD in MOPS-preserved OCAs will be significantly higher than for standard tissue bank preservation. Media changes during preservation will significantly improve the VCD. Study Design: Controlled laboratory study. Methods: Femoral condyles harvested from qualified donors (n = 12) were quartered (n = 48), assigned to 1 of 4 treatment groups (tissue bank protocol at 4°C or MOPS at 25°C, with or without media changes), and preserved for 0, 28, 56, or 70 days and assessed for the VCD and histopathological characteristics. In addition, osteochondral explants were created from the femoral condyles of 12 donors (n = 36 explants), assigned to the same groups and time points, and tested for biomechanical properties. Results: MOPS-preserved OCAs maintained the day 0 VCD through 56 days. OCAs stored using current tissue bank protocols had a significantly lower VCD compared with day 0 and the MOPS by day 28. OCA histological and biomechanical properties did not significantly change from day 0 for any group. Conclusion: The MOPS preserved essential OCA viability and quality at significantly higher levels than current tissue bank protocols for at least 56 days after procurement. Clinical Relevance: Improving the viability and duration of OCA preservation provides potential benefits to tissue banks, donor families, surgeons, and patients with respect to tissue use, financial costs, and outcomes.

25 September 2015 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
JCJames L. Cook
James L. Cook
PSPatrick A. Smith
Patrick A. Smith
CBChantelle Bozynski
Chantelle Bozynski
KKKeiichi Kuroki
Keiichi Kuroki
CCCristi R. Cook
Cristi R. Cook
FPFerris M. Pfeiffer
Ferris M. Pfeiffer
Platelet rich plasma (PRP) is used to treat many musculoskeletal disorders. We used a canine model to determine the effects of multiple intra‐articular injections of leukoreduced PRP (ACP) on anterior cruciate ligament healing, meniscal healing, and progression of osteoarthritis (OA). With Animal Care and Use Committee (ACUC) approval, 12 dogs underwent partial ACL transection and meniscal release in one knee. At weeks 1, 2, 3, 6, and 8 after insult, dogs were treated with intra‐articular injections (2 ml) of either ACP (n = 6) or saline (n = 6). Dogs were assessed over 6 months to determine comfortable range of motion (CROM), lameness, pain, effusion, kinetics, and radiographic and arthroscopic assessments. At 6‐month endpoint, dogs were assessed for ACL material properties and histopathology. Saline‐treated dogs had significantly (p < 0.04) more CROM loss, significantly (p < 0.01) more pain, significantly (p < 0.05) more severe lameness, significantly (p < 0.05) lower function, and significantly (p < 0.05) lower %Total Pressure Index in affected hindlimbs compared to ACP‐treated dogs. Radiographic OA increased significantly (p < 0.01) over time within each group. Arthroscopically, saline‐treated knees showed moderate to severe synovitis, further ACL disruption, and medial compartment cartilage loss, and ACP‐treated knees showed evidence of ACL repair and less severe synovitis. ACL material properties in ACP‐treated knees were closer to normal than in saline‐treated knees, however, the differences were not statistically significant. ACL histopathology was significantly (p< 0.05) less severe in ACP‐treated knees compared to saline‐treated knees. Five intra‐articular injections of leukoreduced PRP had beneficial effects for ACL healing, improved range of motion, decreased pain, and improved limb function for up to 6 months in this model. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:607–615, 2016.

4 February 2016 in Arthroscopy
Verified
Journal Article
Closed access
PSPatrick A. Smith
Patrick A. Smith
JSJames P. Stannard
James P. Stannard
FPFerris M. Pfeiffer
Ferris M. Pfeiffer
KKKeiichi Kuroki
Keiichi Kuroki
CBChantelle Bozynski
Chantelle Bozynski
JCJames L. Cook
James L. Cook

1 January 2003 in Animal Behaviour
Verified
Journal Article
Closed access
CBChantelle Bozynski
Chantelle Bozynski
NLN. Robin Liley
N. Robin Liley